Mode
Text Size
Log in / Sign up

SARS-CoV-2 related microvascular thrombosis is associated with increased risk of acute kidney injurySmall blood clots in COVID-19 patients link to kidney damage

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that SARS-CoV-2 related microvascular thrombosis is associated with increased risk of acute kidney injury.

This systematic review synthesizes evidence regarding the association between SARS-CoV-2 related microvascular thrombosis and acute kidney injury (AKI) in patients with COVID-19, including hospitalized, critically ill, and pediatric populations. The authors conclude that microvascular or thrombotic events are associated with an increased risk of adverse renal outcomes (OR 2.14; 95%CI 1.32-3.48).

Specific incidence rates for AKI were reported across different patient cohorts: 9.2% in hospitalized patients, 32.6% in critically ill patients, and 20% in children with multisystem inflammatory syndrome associated with SARS-CoV-2. Furthermore, the presence of AKI was associated with an increased risk of mortality (OR 4.68; 95%CI 1.06-20.70) and a greater likelihood of requiring renal replacement therapy (OR 2.87; 95%CI 1.45-5.68).

The certainty of evidence for these primary outcomes ranges from moderate to high. These findings suggest that microvascular thrombotic injury is associated with COVID-19 related AKI, highlighting the need for early renal monitoring and risk stratification in high-risk patients.

When a person catches COVID-19, the virus can cause problems beyond just the lungs. One specific issue is microvascular thrombosis, which means tiny blood clots forming in the smallest blood vessels of the body. This review looked at how these small clots affect kidney health in patients with COVID-19, including those who were critically ill or children with severe symptoms.

The data shows a clear link between these small clotting events and acute kidney injury, which is a sudden decrease in kidney function. For example, about 32.6% of critically ill patients developed this kidney damage. Furthermore, patients with these blood clots faced a much higher risk of needing renal replacement therapy, which is a form of dialysis to do the work of the kidneys.

While the evidence for this link is strong, it is important to remember that this was a review of existing data rather than a new clinical trial. The findings suggest that doctors should monitor kidney health closely and early in the treatment of high-risk patients to help protect their organs from these complications.

What this means for you:
Small blood clots in tiny vessels are strongly linked to kidney damage and higher risks for COVID-19 patients.

Common questions

What is the link between blood clots and kidney health in COVID-19?

Small blood clots in tiny vessels, called microvascular thrombosis, are linked to acute kidney injury. Patients with these clotting events had a much higher risk of needing renal replacement therapy, which is a treatment like dialysis used when kidneys cannot function on their own.

How common was kidney damage in critically ill COVID-19 patients?

In the study of hospitalized cases, about 32.6% of critically ill patients experienced acute kidney injury. This condition is a sudden loss of function in the kidneys.

Does this finding affect children with severe COVID-19?

Yes, the data included children with multisystem inflammatory syndrome associated with SARS-CoV-2. In these cases, 20% of the children experienced acute kidney injury.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Abstract Objective: To synthesize the available evidence on the association between SARS-CoV-2-related microvascular thrombosis and acute kidney injury (AKI), with emphasis on renal outcomes, mortality, and renal replacement therapy requirements. Methods: This systematic review followed the PRISMA 2020 statement and was prospectively registered in PROSPERO (CRD420251132701). PubMed/MEDLINE, Scopus, and Embase were searched for systematic reviews, including meta-analyses, and umbrella reviews investigating the association between SARS-CoV-2-related microvascular thrombosis and acute kidney injury. Two reviewers independently performed study selection, data extraction, and methodological quality assessment using AMSTAR-2 and ROBIS. Evidence was synthesized through a structured narrative synthesis supported by quantitative data extracted from the included reviews. Results: Six evidence syntheses evaluating kidney involvement, thrombotic events, and microvascular mechanisms in COVID-19 were included. AKI incidence was 9.2% (95%CI 4.6-13.9) among hospitalized patients and 32.6% (95%CI 8.5-56.6) among critically ill patients. In children with multisystem inflammatory syndrome associated with SARS-CoV-2, AKI incidence was 20% (95%CI 14-28). Microvascular or thrombotic events were associated with adverse renal outcomes (OR 2.14; 95%CI 1.32-3.48). AKI was associated with increased mortality (OR 4.68; 95%CI 1.06-20.70) and greater likelihood of renal replacement therapy requirement (OR 2.87; 95%CI 1.45-5.68). The certainty of evidence ranged from moderate to high for the principal outcomes. Conclusion: Current evidence supports an important association between microvascular thrombotic injury and COVID-19-associated AKI. These findings reinforce the relevance of endothelial dysfunction and thromboinflammatory pathways in kidney involvement during COVID-19 and highlight the need for early renal monitoring, risk stratification, and kidney-protective strategies in high-risk patients. Keywords: COVID-19; Acute Kidney Injury; Microvascular Thrombosis; SARS-CoV-2; Renal Replacement Therapy; Systematic Review
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.